RYE, N.Y., Nov. 2, 2010 /PRNewswire/ — Curemark LLC, a
drug research and development company focused on the treatment of
neurological diseases, announced today that it has been awarded a
grant by the United States government under the Qualifying
Therapeutic Discovery Project (QTDP) Program to advance the
development of its lead product CM-AT for autism. CM-AT is
presently in Phase III clinical trials at 18 sites around the
US.
The QTDP grant program provides support for innovative projects
that are determined by the U.S. Department of Health and Human
Services to have reasonable potential to result in a new therapy,
reduce health care costs, or significantly advance the goal of
curing cancer. The QTDP program was created by Congress on May 21,
2010 under Section 48D of the Internal Revenue Code, as enacted
under the Patient Protection and Affordable Care Act.
Dr. Joan Fallon, Curemark CEO, commented: “We are very
appreciative of the recognition and support provided by this award
for CM-AT that has the potential to treat the symptoms of autism,
and also provide significant economic benefits to our
community.”
CM-AT, Curemark’s autism treatment, targets enzyme deficiencies
in autistic children that affect the availability of amino acids,
the building blocks of chemicals essential for brain function. The
company is currently conducting Phase III CM-AT trials at 18 sites
nationwide with a planned total of 170 children. If approved,
CM-AT, which has been granted Fast Track status from the FDA, will
be one of the first therapies to address the underlying physiology
of autism.
About CUREMARK LLC
Curemark is a drug research and development company focused on
the treatment of neurological and other diseases, especially those
with dysautonomic components, by addressing certain key
gastrointestinal/pancreatic secretory deficiencies. The company’s
initial products are based upon breakthro
‘/>”/>
SOURCE
